Plant sterols and their role in combined use with statins for lipid lowering

Current Opinion in Investigational Drugs

Volumn 6, Issue 3, 2005, Pages 307-316

  Normén, Lena ^a   Holmes, Daniel ^a   Frohlich, Jiri ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cholesterol; Coronary heart disease; Phytosterols; Plant sterols; Statins

Indexed keywords

ABC TRANSPORTER; AMINOTRANSFERASE; APOLIPOPROTEIN B100; ATORVASTATIN; BRASSICASTEROL; CAMPESTANOL; CAMPESTEROL; CAROTENOID; CERIVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER; CREATINE KINASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PHYTOSTEROL; PRAVASTATIN; SATURATED FATTY ACID; SIMVASTATIN; SITOSTANOL; SITOSTEROL; STANOL ESTER; STIGMASTEROL; TRIACYLGLYCEROL; UNINDEXED DRUG; UNSATURATED FATTY ACID;

ARTERIOSCLEROSIS; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HEALTH CARE COST; HEART ARREST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPOCHOLESTEROLEMIA; LIPID ABSORPTION; LIPID DIET; LIPID HYDROLYSIS; LIPID METABOLISM; LIPID SOLUBILITY; LIPID TRANSPORT; LIVER TOXICITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEPHROTOXICITY; PLANT FIBER; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; UNSTABLE ANGINA PECTORIS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CLINICAL TRIALS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MOLECULAR STRUCTURE; PHYTOSTEROLS;

EID: 15844383092     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk. Lancet (2003) 361(9359):717-725.
2. 2002 Heart and stroke statistical update. American Heart Association, Dallas, TX, USA (2001):1-38.
3. The growing burden of heart disease and stroke in Canada 2003. The Heart and Stroke Foundation of Canada, Ottawa, Canada (2003).
4. Ezzati M, Lopez AD, Rodgers A, Vander Hoom S, Murray CJ: Selected major risk factors and global and regional burden of disease. Lancet (2002) 360(9343):1347-1360.
5. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 345 22):1583-1592.
6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet (2004) 364(9438):937-952.
7. Law MR, Wald NJ: An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr (1994) 48(5):305-325.
8. Jarvis D, McDonald K, Marcotte M, Smith B, Stanford L: Business and market impact of the food and drugs act of regulations on functional foods in Canada. Inter/Sect Alliance Inc, for Food Bureau Agri-culture and Agri-Food Canada (2001):1-139.
9. Weststrate JA, Meijer GW: Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr (1998) 52(5):334-343.
10. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med (1995) 333 20):1308-1312.
11. Kochhar S: Influence of processing on sterols of edible vegetable oils. Prog Lipid Res (1983) 22(3):161-188.
12. Nes W: Multiple roles for phytosterols. In: The Metabolism, Structure and Function of Plant Lipids. Stumpf P (Ed), Plenum Press, New York, NY, USA (1987):3-9.
13. Weihrauch JL, Gardner JM: Sterol content of foods of plant origin. J Am Diet Assoc (1978) 73(1):39-47.
14. Normen L, Johnsson M, Andersson H, van Gameren Y, Dutta P: Plant sterols in vegetables and fruits commonly consumed in Sweden. Eur J Nutr (1999) 38(2):84-89.
15. Piironen V, Toivo J, Lampi A-M: Natural sources of dietary plant sterols. J Food Comp Analys (2000) 13(4):619-624.
16. Cerqueira MT, Fry MM, Connor WE: The food and nutrient intakes of the Tarahumara Indians of Mexico. Am J Clin Nutr (1979) 32 4):905-915.
17. Morton G, Lee S, Buss D, Lawrance P: Intakes and major dietary sources of cholesterol and phytosterols in the British diet. J Hum Nutr Diet (1995) 8:429-440.
18. Normen AL, Brants HA, Voorrips LE, Andersson HA, van den Brandt PA, Goldbohm RA: Plant sterol intakes and colorectal cancer risk in the Netherlands Cohort Study on Diet and Cancer. Am J Clin Nutr (2001) 74(1):141-148.
19. Hirai K, Shimazu C, Takezoe R, Ozeki Y: Cholesterol, phytosterol and polyunsaturated fatty acid levels in 1982 and 1957 Japanese diets. J Nutr Sci Vitaminol (1986) 32(4):363-372.
20. Strom SS, Yamamura Y, Duphome CM, Spitz MR, Babaian RJ, Pillow PC, Hursting SD: Phytoestrogen intake and prostate cancer: A case-control study using a new database. Nutr Cancer (1999) 33 1):20-25.
21. Nair PP, Turjman N, Kessie G, Calkins B, Goodman GT, Davidovitz H, Nimmagadda G: Diet, nutrition intake, and metabolism in populations at high and low risk for colon cancer. Dietary cholesterol, β-sitosterol, and stigmasterol. Am J Clin Nutr (1984) 40 4 Suppl):927-930.
22. Andersson SW, Skinner J, Ellegard L, Welch AA, Bingham S, Mulligan A, Andersson H, Khaw KT: Intake of dietary plant sterols is inversely related to serum cholesterol concentration in men and women in the EPIC Norfolk population: A cross-sectional study. Eur J Clin Nutr (2004) 58(10):1378-1385.
23. Normén L, Dutta P, Lia A, Andersson H: Soy sterol esters and β-sitostanol ester as inhibitors of cholesterol absorption in human small bowel. Am J Clin Nutr (2000) 71(4):908-913.
24. Normen L, Ellegård L, Janssen H-G, Steenbergen H, Trautwein E, Andersson H: Hydrolysis of phytosterol and phytostanol esters in the gut and their effects on fat digestion in ileostomy subjects. Eur J Nutr (2005): manuscript submitted.
25. Plat J, Mensink RP: Increased intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption. FASEB J (2002) 16(10):1248-1253.
26. Field FJ, Born E, Mathur SN: LXR/RXR ligand activation enhances basolateral efflux of β-sitosterol in CaCo-2 cells. J Lipid Res (2004) 45(5):905-913.
27. Field FJ, Born E, Mathur SN: Stanol esters decrease plasma cholesterol independently of intestinal ABC sterol transporters and Niemann-Pick C1-like 1 protein gene expression. J Lipid Res (2004) 45(12):2252-2259.
28. Jandacek RJ, Webb MR, Mattson FH: Effect of an aqueous phase on the solubility of cholesterol in an oil phase. J Lipid Res (1977) 18(2):203-210.
29. Borgstrom B: Quantitative aspects of the intestinal absorption and metabolism of cholesterol and β-sitosterol in the rat. J Lipid Res (1968) 9(4):473-481.
30. Ikeda I, Sugano M: Some aspects of mechanism of inhibition of cholesterol absorption by β-sitosterol. Biochim Biophys Acta (1983) 732(3):651-658.
31. Jones PJ, Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Feng JY, Parsons WE: Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res (2000) 41 5):697-705.
32. Vanhanen HT, Kajander J, Lehtovirta H, Miettinen TA: Serum levels, absorption efficiency, faecal elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in hypercholesterolaemic subjects. Clin Sci (1994) 87 1):61-67.
33. Gylling H, Miettinen TA: Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia (1994) 37(8):773-780.
34. Gylling H, Miettinen TA: Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res (1996) 37(8):1776-1785.
35. Gylling H, Miettinen TA: The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level. Atherosclerosis (1995) 117(2):305-308.
36. Plat J, Mensink RP: Effects of plant stanol esters on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase mRNA expression in mononuclear blood cells of healthy men and women. FASEB J (2002) 16(2):258-260.
37. Hallikainen MA, Sarkkinen ES, Uusitupa MI: Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr (2000) 130(4):767-776.
38. Hendriks HF, Weststrate JA, van Vliet T, Meijer GW: Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr (1999) 53 4):319-327.
39. Ellegård L, Bosaeus I, Andersson H: Will recommended changes in fat and fibre intake affect cholesterol absorption and sterol excretion? An ileostomy study. Eur J Clin Nutr (2000) 54(4):306-313.
40. Ostlund RE Jr, Racette SB, Okeke A, Stenson WF: Phytosterols that are naturally present in commercial corn oil significantly reduce cholesterol absorption in humans. Am J Clin Nutr (2002) 75 6):1000-1004.
41. Perez-Jimenez F, Lopez-Miranda J, Pinillos MD, Gomez P, Paz-Rojas E, Montilla P, Marin C, Velasco MJ, Blanco-Molina A, Jimenez Pereperez JA, Ordovas JM: A mediterranean and a high-carbohydrate diet improve glucose metabolism in healthy young persons. Diabetologia (2001) 44(11):2038-2043.
42. Howell TJ, MacDougall DE, Jones PJ: Phytosterols partially explain differences in cholesterol metabolism caused by corn or olive oil feeding. J Lipid Res (1998) 39(4):892-900.
43. Ayesh R, Weststrate JA, Drewitt PN, Hepburn PA: Safety evaluation of phytosterol esters. Part 5. Faecal short-chain fatty acid and microflora content, faecal bacterial enzyme activity and serum female sex hormones in healthy normolipidaemic volunteers consuming a controlled diet either with or without a phytosterol ester-enriched margarine. Food Chem Toxicol (1999) 37(12):1127-1138.
44. Davidson MH, Maki KC, Umporowicz DM, Ingram KA, Dicklin MR, Schaefer E, Lane RW, McNamara JR, Ribaya-Mercado JD, Perrone G, Robins SJ, Franke WC: Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. J Am Coll Nutr (2001) 20(4):307-319.
45. Geelen A, Zock PL, de Vries JH, Katan MB: Apolipoprotein E polymorphism and serum lipid response to plant sterols in humans. Eur J Clin Invest (2002) 32(10):738-742.
46. Gylling H, Radhakrishnan R, Miettinen TA: Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: Women and dietary sitostanol. Circulation (1997) 96(12):4226-4231.
47. Hendriks HF, Brink EJ, Meijer GW, Princen HM, Ntanios FY: Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr (2003) 57(5):681-692.
48. Ishiwata K, Homma Y, Ishikawa T, Nakamura H, Handa S: Influence of apolipoprotein E phenotype on metabolism of lipids and apolipoproteins after plant stanol ester ingestion in Japanese subjects. Nutrition (2002) 18(7-8):561-565.
49. Judd J, Baer D, Clevidence B, Muesing R, Chen SC, Meijer G: Dietary fat and fatty acids and plasma modifying effects of sterol esters. FASEB J (2001) 15(A639):Abs 503.8.
50. Judd JT, Baer DJ, Chen SC, Clevidence BA, Muesing RA, Kramer M, Meijer GW: Plant sterol esters lower plasma lipids and most carotenoids in mildly hypercholesterolemic adults. Lipids (2002) 37 1):33-42.
51. Matvienko OA, Lewis DS, Swanson M, Arndt B, Rainwater DL, Stewart J, Alekel DL: A single daily dose of soybean phytosterols in ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly hypercholesterolemic men. Am J Clin Nutr (2002) 76 1):57-64.
52. Mensink RP, Ebbing S, Lindhout M, Plat J, van Heugten MM: Effects of plant stanol esters supplied in low-fat yoghurt on serum lipids and lipoproteins, non-cholesterol sterols and fat soluble antioxidant concentrations. Atherosclerosis (2002) 160(1):205-213.
53. Miettinen TA, Vuoristo M, Nissinen M, Jarvinen HJ, Gylling H: Serum, biliary, and fecal cholesterol and plant sterols in colectomized patients before and during consumption of stanol ester margarine. Am J Clin Nutr (2000) 71(5):1095-1102.
54. Niinikoski H, Viikari J, Palmu T: Cholesterol-lowering effect and sensory properties of sitostanol ester margarine in normocholesterolemic adults. Scand J Nutr (1997) 41:9-12.
55. Pelletier X, Belbraouet S, Mirabel D, Mordret F, Perrin JL, Pages X, Debry G: A diet moderately enriched in phytosterols lowers plasma cholesterol concentrations in normocholesterolemic humans. Ann Nutr Metab (1995) 39(5):291-295.
56. Plat J, van Onselen EN, van Heugten MM, Mensink RP: Effects on serum lipids, lipoproteins and fat soluble antioxidant concentrations of consumption frequency of margarines and shortenings enriched with plant stanol esters. Eur J Clin Nutr (2000) 54(9):671-677.
57. Sierksma A, Weststrate JA, Meijer GW: Spreads enriched with plant sterols, either esterified 4,4-dimethylsterols or free 4-desmethylsterols, and plasma total- and LDL-cholesterol concentrations. Br J Nutr (1999) 82(4):273-282.
58. Plat J, Mensink RP: Vegetable oil based versus wood based stanol ester mixtures: Effects on serum lipids and hemostatic factors in non-hypercholesterolemic subjects. Atherosclerosis (2000) 148(1):101-112.
59. Spilburg CA, Goldberg AC, McGill JB, Stenson WF, Racette SB, Bateman J, McPherson TB, Ostlund RE Jr: Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterol. J Am Diet Assoc (2003) 103(5):577-581.
60. Temme EH, Van Hoydonck PG, Schouten EG, Kesteloot H: Effects of a plant sterol-enriched spread on serum lipids and lipoproteins in mildly hypercholesterolaemic subjects. Acta Cardiol (2002) 57 2):111-115.
61. Vissers MN, Zock PL, Meijer GW, Katan MB: Effect of plant sterols from rice bran oil and triterpene alcohols from peanut oil on serum lipoprotein concentrations in humans. Am J Clin Nutr (2000) 72(6):1510-1515.
62. Vuorio AF, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen TA: Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. Arterioscler Thromb Vasc Biol (2000) 20(2):500-506.
63. Andersson A, Karlstrom B, Mohsen R, Vessby B: Cholesterol-lowering of a stanol ester-containing low-fat margarine in conjunction with a strict lipid-lowering diet. Eur Heart J (1999) 1:S80-S90.
64. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB: Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol (2000) 86(1):46-52.
65. Christiansen LI, Lahteenmaki PL, Mannelin MR, Seppanen-Laakso TE, Hiltunen RV, Yliruusi JK: Cholesterol-lowering effect of spreads enriched with microcrystalline plant sterols in hypercholesterolemic subjects. Eur J Nutr (2001) 40(2):66-73.
66. Clifton PM, Noakes M, Sullivan D, Erichsen N, Ross D, Annison G, Fassoulakis A, Cehun M, Nestel P: Cholesterol-lowering effects of plant sterol esters differ in milk, yoghurt, bread and cereal. Eur J Clin Nutr (2004) 58(3):503-509.
67. Clifton PM, Noakes M, Ross D, Fassoulakis A, Cehun M, Nestel P: High dietary intake of phytosterol esters decreases carotenoids and increases plasma plant sterol levels with no additional cholesterol lowering. J Lipid Res (2004) 45(8):1493-1499.
68. De Graaf J, De Sauvage Nolting PR, Van Dam M, Belsey EM, Kastelein JJ, Haydn Pritchard P, Stalenhoef AF: Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels. Br J Nutr (2002) 88(5):479-488.
69. Denke MA: Lack of efficacy of low-dose sitostanol therapy as an adjunct to a cholesterol-lowering diet in men with moderate hypercholesterolemia. Am J Clin Nutr (1995) 61(2):392-396.
70. Devaraj S, Jialal I, Vega-Lopez S: Plant sterol-fortified orange juice effectively lowers cholesterol levels in mildly hypercholesterolemic healthy individuals. Arterioscler Thromb Vasc Biol (2004) 24(3):e25-e28.
71. Gylling H, Puska P, Vartiainen E, Miettinen TA: Serum sterols during stanol ester feeding in a mildly hypercholesterolemic population. J Lipid Res (1999) 40(4):593-600.
72. Hallikainen MA, Sarkkinen ES, Uusitupa MI: Effects of low-fat stanol ester enriched margarines on concentrations of serum carotenoids in subjects with elevated serum cholesterol concentrations. Eur J Clin Nutr (1999) 53(12):966-969.
73. Hallikainen MA, Sarkkinen ES, Gylling H, Erkkila AT, Uusitupa MI: Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet. Eur J Clin Nutr (2000) 54(9):715-725.
74. Heinemann T, Leiss O, von Bergmann K: Effect of low-dose sitostanol on serum cholesterol in patients with hypercholesterolemia. Atherosclerosis (1986) 61(3):219-223.
75. Jones PJ, Howell T, MacDougall DE, Feng JY, Parsons W: Short-term administration of tall oil phytosterols improves plasma lipid profiles in subjects with different cholesterol levels. Metabolism (1998) 47(6):751-756.
76. Maki KC, Davidson MH, Umporowicz DM, Schaefer EJ, Dicklin MR, Ingram KA, Chen S, McNamara JR, Gebhart BW, Ribaya-Mercado JD, Perrone G et al Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet. Am J Clin Nutr (2001) 74(1):33-43.
77. Miettinen TA, Vanhanen H: Dietary sitostanol related to absorption, synthesis and serum level of cholesterol in different apolipoprotein E phenotypes. Atherosclerosis (1994) 105(2):217-226.
78. Neil HA, Meijer GW, Roe LS: Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis (2001) 156(2):329-337.
79. Nestel P, Cehun M, Pomeroy S, Abbey M, Weldon G: Cholesterol-lowering effects of plant sterol esters and non-esterified stanols in margarine, butter and low-fat foods. Eur J Clin Nutr (2001) 55 12):1084-1090.
80. Nguyen TT, Dale LC, von Bergmann K, Croghan IT: Cholesterol-lowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women: A randomized controlled trial. Mayo Clin Proc (1999) 74(12):1198-1206.
81. Nigon F, Serfaty-Lacrosniere C, Beucler I, Chauvois D, Neveu C, Giral P, Chapman MJ, Bruckert E: Plant sterol-enriched margarine lowers plasma LDL in hyperlipidemic subjects with low cholesterol intake: Effect of fibrate treatment. Clin Chem Lab Med (2001) 39(7):634-640.
82. Noakes M, Clifton P, Ntanios F, Shrapnel W, Record I, McInerney J: An increase in dietary carotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations. Am J Clin Nutr (2002) 75(1):79-86.
83. Noakes M, Clifton PM, Doornbos AM, Trautwein EA: Plant sterol ester-enriched milk and yoghurt effectively reduce serum cholesterol in modestly hypercholesterolemic subjects. Eur J Nutr (2004): DOI:10.1007/s00394-004-0513-Z.
84. Simons LA: Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol (2002) 90(7):737-740.
85. Thomsen AB, Hansen HB, Christiansen C, Green H, Berger A: Effect of free plant sterols in low-fat milk on serum lipid profile in hypercholesterolemic subjects. Eur J Clin Nutr (2004) 58 6):860-870.
86. Vanhanen HT, Blomqvist S, Ehnholm C, Hyvonen M, Jauhiainen M, Torstila I, Miettinen TA: Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment. J Lipid Res (1993) 34(9):1535-1544.
87. Vanhanen H: Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in prevastatin-treated hypercholesterolaemic patients. Eur J Clin Pharmacol (1994) 47(2):169-176.
88. Vanstone CA, Raeini-Sarjaz M, Parsons WE, Jones PJ: Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am J Clin Nutr (2002) 76(6):1272-1278.
89. Lee Y-M, Haastert H, Sherbaum W, Hauner H: Ambulante studie sur wirkung von phytosterol-angerichter margarine auf den lipidstatus von typ-2 diabetilkern. Proc Germ Nutr Soc (2001) 3(7):Abs V9.
90. Food labeling: Health Claims; Plant sterol/stanol esters and coronary heart disease. Food and Drug Administration, Washington, DC, USA (2000):54685-54739.
91. Cooney RV, Franke AA, Hankin JH, Custer LJ, Wilkens LR, Harwood PJ, Le Marchand L: Seasonal variations in plasma micronutrients and antioxidants. Cancer Epidemiol Biomarkers Prev (1995) 4 3):207-215.
92. Glueck CJ, Speirs J, Tracy T, Streicher P, Illig E, Vandegrift J: Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives. Metabolism (1991) 40(8):842-848.
93. Sudhop T, Gottwald BM, von Bergmann K: Serum plant sterols as a potential risk factor for coronary heart disease. Metabolism (2002) 51(12):1519-1521.
94. Assmann G, Cullen P, Erbey J, Ramey D, Kannenberg F, Schulte H: Elevation in plasma sitosterol concentrations is associated with increased risk for coronary events in the PROCAM study. Annual Meeting of the American Heart Association November 2-5 Orlando, FL, USA (2003) 23:Abs 108.
95. Berge KE, von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC: Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res (2002) 43(3):486-494.
96. Wilund KR, Yu L, Xu F, Vega GL, Grundy SM, Cohen JC, Hobbs HH: No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler Thromb Vasc Biol (2004) 24 12):2326-2332.
97. Endo A, Kuroda M, Tsujita Y: ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (1976) 29(12):1346-1348.
98. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A et al: Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA (1980) 77(7):3957-3961.
99. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 333 20):1301-1307.
100. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc (1998) 279 20):1615-1622.
101. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J et al: Prevention of coronary and stroke events with storvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet (2003) 361(9364):1149-1158.
102. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc (2002) 288 23):2981-2997.
103. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet (2002) 360(9326):7-22.
104. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet (2004) 364(9435):685-696.
105. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Sinivastatin Survival Study (4S). Lancet (1994) 344(8934):1383-1389.
106. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 335 14):1001-1009.
107. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med (1998) 339(19):1349-1357.
108. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med (1999) 341(2):70-76.
109. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. J Am Med Assoc (2001) 285(13):1711-1718.
110. Gemici G, Toprak A, Oktay A: Rhabdomyolysis due to cerivastatin monotherapy. Am J Med (2001) 110(9):742.
111. Bellosta S, Paoletti R, Corsini A: Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation (2004) 109(23 Suppl 1):III50-III57.
112. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C: ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation (2002) 106(8):1024-1028.
113. Jamal SM, Eisenberg MJ, Christopoulos S: Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J (2004) 147(6):956-965.
114. ATPIII: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on "Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)". National Cholesterol Education Program. National Heart, Lung and Blood Institute. National Institutes of Health, MD, USA (2001).
115. Civeira F: Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis (2004) 173(1):55-68.
116. SCS: Dietary recommendations. Spanish Cardiology Society/Spanish Health Minister, Celia Villalobos, Spain (2001).
117. Cholesterol Lowering Diet. Diet in the promotion of heart health. Association of Clinical and Public Health Nutritionists in Finland (2002).
118. Plant sterols and stanols. A position statement from the Heart Foundation's Nutrition and Metabolism Advisory Committee. National Heart Foundation of Australia (1999).
119. Miettinen TA, Strandberg TE, Gylling H: Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: Relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol (2000) 20(5):1340-1346.
120. Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR: Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol (2003) 25(6):457-481.
121. Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus sinivastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol (1998) 81(5):582-587.
122. Gagne C, Gaudet D, Bruckert E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation (2002) 105(21):2469-2475.
123. Ezzet F, Wexler D, Statkevich P, Kosoglou T, Patrick J, Lipka L, Mellars L, Veltri E, Batra V: The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol (2001) 41 9):943-949.
124. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H: Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med (2003) 141 2):131-137.
125. Bhattacharyya AK, Connor WE, Lin DS, McMurry MM, Shulman RS: Sluggish sitosterol turnover and hepatic failure to excrete sitosterol into bile cause expansion of body pool of sitosterol in patients with sitosterolemia and xanthomatosis. Arterioscler Thromb (1991) 11(5):1287-1294.
126. Nguyen LB, Salen G, Shefer S, Bullock J, Chen T, Tint GS, Chowdhary IR, Lerner S: Deficient ileal 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in sitosterolemia: Sitosterol is not a feedback inhibitor of intestinal cholesterol biosynthesis. Metabolism (1994) 43(7):855-859.
127. Salen G, Shore V, Tint GS, Forte T, Shefer S, Horak I, Horak E, Dayal B, Nguyen L, Batta AK, Lindgren FT, Kwiterovich PO: Increased sitosterol absorption, decreased removal, and expanded body pools compensate for reduced cholesterol synthesis in sitosterolemia with xanthomatosis. J Lipid Res (1989) 30(9):1319-1330.
128. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol (2003) 92(2):152-160.
129. Roberts WC: The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol (1997) 80(1):106-107.
130. Gotto A, Pownall H: Reducing the risk for coronary heart disease. In: Manual of Lipid Disorders, 3rd Edition. Lippincott Williams and Wilkins, Baltimore, MD, USA (2003):171-172.